Literature DB >> 33596144

The Era of the Coronavirus Disease 2019 Pandemic: A Review on Dynamics, Clinical Symptoms and Complications, Diagnosis, and Treatment.

Nour K Younis1, Rana O Zareef1, Mohammad Ali N Maktabi1, Rami Mahfouz2.   

Abstract

Coronavirus disease 2019 (COVID-19) displays a broad spectrum of clinical presentations ranging from lack of symptoms to severe multiorgan system complications and death. Various laboratory assays have been employed in the diagnosis of COVID-19, including: nucleic acid-based tests; antigen tests; and serum testing for anti-severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) antibodies. The disease can also be diagnosed based on suggestive clinical features and radiological findings. Until now, remdesivir is the only medication approved for the treatment of COVID-19 by the U.S. Food and Drug Administration (FDA); however, it is anticipated that several anti-SARS-CoV-2 monoclonal antibodies will gain soon approval. Other methods of treatment include supportive care directed toward treating the symptoms. Nevertheless, many studies have recently emerged, showing controversial preliminary results with the off-label medication hydroxychloroquine. Given that all results are still preliminary, including those seen by remdesivir, additional evidence and research are required to identify effective medications that are broadly effective and well tolerated. Importantly, two RNA-based vaccines have recently gained approval from Pfizer and Moderna, with many others still in clinical trials. This article reviews various aspects of COVID-19, including its epidemiology; its evolution and mutational spectrum; and its clinical dynamics, symptoms and complications, diagnosis, and treatment.

Entities:  

Keywords:  COVID-19; SARS-CoV-2; coronavirus; review

Year:  2021        PMID: 33596144     DOI: 10.1089/gtmb.2020.0227

Source DB:  PubMed          Journal:  Genet Test Mol Biomarkers        ISSN: 1945-0257


  4 in total

1.  Elevated plasma level of the glycolysis byproduct methylglyoxal on admission is an independent biomarker of mortality in ICU COVID-19 patients.

Authors:  Fadhel A Alomar; Marai N Alshakhs; Salah Abohelaika; Hassan M Almarzouk; Mohammed Almualim; Amein K Al-Ali; Fahad Al-Muhanna; Mohammed F Alomar; Mousa J Alhaddad; Mohammed S Almulaify; Faisal S Alessa; Ahmed S Alsalman; Ahmed Alaswad; Sean R Bidasee; Hassan A Alsaad; Rudaynah A Alali; Mona H AlSheikh; Mohammed S Akhtar; Mohammed Al Mohaini; Abdulkhaliq J Alsalman; Hussain Alturaifi; Keshore R Bidasee
Journal:  Sci Rep       Date:  2022-06-09       Impact factor: 4.996

Review 2.  COVID-19: potential therapeutics for pediatric patients.

Authors:  Nour K Younis; Rana O Zareef; Ghina Fakhri; Fadi Bitar; Ali H Eid; Mariam Arabi
Journal:  Pharmacol Rep       Date:  2021-08-30       Impact factor: 3.024

Review 3.  Risk versus Benefit of Using Hydroxychloroquine to Treat Patients with COVID-19.

Authors:  George G Zhanel; Michael A Zhanel; Kevin F Boreskie; Joseph P Lynch; James A Karlowsky
Journal:  Can J Infect Dis Med Microbiol       Date:  2021-09-15       Impact factor: 2.471

Review 4.  Aspirin in COVID-19: Pros and Cons.

Authors:  Rana Zareef; Marwa Diab; Tala Al Saleh; Adham Makarem; Nour K Younis; Fadi Bitar; Mariam Arabi
Journal:  Front Pharmacol       Date:  2022-03-10       Impact factor: 5.810

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.